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Abstract

Raloxifene (RLX), a BCS class-II drug is a selective estrogen receptor modulator (SERM) having
estrogenic effect on bone and antiestrogenic effect on endometrium and breast, respectively. Low
solubility, high permeability, high metabolism and low bioavailability are the characteristics of
raloxifene. Although 60% is absorbed orally, raloxifene shows extremely poor bioavailability (2%)
owing to its low solubility and an extensive (>90%) intestinal/hepatic first-pass metabolism. Hence
it becomes important to increase the solubility of raloxifene in order to enhance its bioavailability. In
this study, Raloxifene nanostructured lipid carriers (RNLCs) were successfully prepared using melt
dispersion ultrasonication method. The prepared RNLCs were characterized, and the in-vitro
studies were carried out in the human epithelial breast cancer cell line (MCF-7 cell line). The
RNLCs have a size of 114.8±0.98 nm and zeta potential of +9.21±0.58 mV. TEM images showed
the particle size ranging from 65nm to 120nm. With an entrapment efficiency of 75.04%±2.75%,
the RNLCs showed sustained release over seven days’ time compared to 24 hours for raloxifene
drug solution. The prepared RNLCs were successfully take up by the MCF-7 cells in time
dependent manner and the RNLCs showed decreased cell viability compared to raloxifene drug.
This suggests the RNLCs were more potent than the raloxifene drug. Using the PAMPA, the
permeability rate for raloxifene solution was calculated to be 8X10−6cm/s and for the RNLCs it was
calculated to be 17.8X10−6 cm/s. Hence, from the Permeability rate calculated, we can conclude
that raloxifene when formulated as NLCs have increased permeability. Overall, the prepared
RNLCs were found to be superior than the raloxifene drug as such.
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Chapter 1: Introduction

Not all the new molecular entities (NMEs) that are synthesized annually by the
pharmaceutical companies are readily soluble in water and hence have poor bioavailability.
Having said that, almost half of the 150,000 NMEs have poor water solubility which reduces the
performance of more than 10% successfully marketed drugs and they have to be administered at
high doses (Shah et al., 2015). Owing to its high patient compliance, oral route is the most
common and widely used route of drug administration (Sharma et al., 2016). However, several
compounds are unsuccessful and unable to reach the market owing to their poor bioavailability
when administered through oral route. Figure 1.1 depicts few of the reasons for poor
bioavailability.
Novel drug delivery system which offers benefits like enhanced permeability, improved
oral bioavailability, low dosage and site-specific targeting can be employed to overcome these
challenges (Poovi et al., 2018). Nanotechnology is a promising strategy that can be used as an
effective tool for enhancing permeation and bioavailability of these drugs and the most common
strategies used are solid lipid nanoparticles (SLNs), polymeric nanoparticles, nanoemulsions,
liposomes, dendrimers, self-nano-emulsifying drug delivery systems and so on. The drugs have
been classified into four groups by the biopharmaceutical classification system (BCS) based on
their solubility and intestinal permeability and there are different conventional and novel
techniques used for enhancing bioavailability of these drugs.
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Figure 1.1. Reasons for poor oral bioavailability of poorly soluble drugs (Sharma et al., 2016)

BCS class II drugs are considered to be best suited for Lipid nanoparticles (LNPs)
formulation compared to class III and IV drugs as 30% of marketed and 60-70% of newly
discovered drugs are BCS class II drugs (Poovi et al., 2018).
Raloxifene (RLX) (Fig 1.2.), a BCS class-II drug is a selective estrogen receptor
modulator (SERM) having estrogenic effect on bone and antiestrogenic effect on endometrium
and breast respectively (Kushwaha et al., 2013). Low solubility, high permeability, high
metabolism and low bioavailability are the characteristics of raloxifene (Elsheikh et al., 2012). It
is used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids.
It is also used to reduce the risk of breast cancer in those at high risk. Although 60% is absorbed
orally, raloxifene shows extremely poor bioavailability (2%) owing to its low solubility and an
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extensive (>90%) intestinal/hepatic first-pass metabolism (Patel et al., 2012). Hence it becomes
important to increase the solubility of raloxifene in order to enhance its bioavailability.

Table 1 Percentage of marketed and new drug molecules according to the BCS classification
system (Poovi et al., 2018)
BCS Class

Properties and Market Size

Class I

High Solubility, High Permeability
Marketed- 35%, Candidates- 5-10%

Class II

Low Solubility, High Permeability
Marketed- 30%, Candidate- 60-70%

Class III

High Solubility, Low Permeability
Marketed- 25%, Candidates- 5-10%

Class IV

Low Solubility, Low Permeability
Marketed- 10%, Candidates- 10-20%

Researchers have explored different approaches in improving the water solubility and
dissolution rate followed by the bioavailability of raloxifene. Some of these approaches are solid
dispersions, self-emulsifying drug delivery systems, complexing with beta cyclodextrins, SLNs,
nanostructured lipid carriers (NLCs) etc. SLNs despite having less toxicity compared to
polymeric nanoparticles but have less drug loading capacity (Shah et al., 2016). As a result, NLCs
have been developed. In one of the researches, inclusion complex of raloxifene with beta
cyclodextrin was designed which lead to 5.5 fold increase in solubility and dissolution rate and 2
fold increase in bioavailability (Shah et al., 2015).

3

Figure 1.2. Structure of Raloxifene

In another research, raloxifene loaded NLCs were prepared, and in vivo pharmacokinetic
study showed 3.75-fold increase in bioavailability (Shah et al., 2016). Similarly, SLN of
raloxifene with glyceryl tribehenate were designed and the bioavailability was enhanced by 3.24
folds when tested in female Wistar rats (Ravi et al., 2014). Further the bioavailability of raloxifene
SLN designed using compritol 888 AT as lipid carrier and Pluronic F68 as surfactant was five
times than that of pure raloxifene (Kushwaha et al., 2013). Higher permeation and 3.5 times
higher bioavailability was recorded in one of the studies where raloxifene SLN were prepared
(Patel et al., 2012).
The aim of this research is to increase the permeability of Raloxifene through
nanoparticle-based drug delivery system and utilize these drugs loaded nanoparticles after their
characterization in the in-vitro analysis of MCF-7 cell line which is the breast cancer cell line.
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1.1 Rationale and Hypothesis
Raloxifene, a BCS class-II drug is a selective estrogen receptor modulator (SERM) having
estrogenic effect on bone and antiestrogenic effect on endometrium and breast respectively
(Kushwaha et al., 2013). Low solubility, high permeability, high metabolism and low
bioavailability are the characteristics of raloxifene (Elsheikh et al., 2012). Although 60% is
absorbed orally, raloxifene shows extremely poor bioavailability (2%) owing to its low solubility
and an extensive (>90%) intestinal/hepatic first-pass metabolism (Patel et al., 2012). Hence it
becomes important to increase the solubility of raloxifene in order to enhance its permeability and
hence bioavailability. Raloxifene undergoes phase II metabolism by the enzyme Uridine 5'diphosphate-glucuronosyltransferase (UGT). Developing a lipid based nano formulation aids in
intestinal lymphatic transport of Raloxifene. The surfactant used in the formulation prevents the
enzyme degradation of drug as it suppresses the metabolism by UGT which in turn increases the
bioavailability of Raloxifene.
Researchers have explored different approaches in improving the water solubility and
dissolution rate followed by the bioavailability of raloxifene. Some of these approaches are solid
dispersions, self-emulsifying drug delivery systems, complexing with beta cyclodextrins, SLNs,
nanostructured lipid carriers (NLCs) etc. Lipid bases nanoformulations like SLNs and NLCs have
unique characteristics that make them suitable candidate for lymphatic delivery. SLNs despite
having less toxicity compared to polymeric nanoparticles, have less drug loading capacity (Shah
et al., 2016). As a result, NLCs have been developed. NLCs have lower water content, increased
drug loading capacity and decreased drug expulsion and hence are physically stable than SLNs.
Hence based on the rationale, it is hypothesized that Raloxifene formulated as
Nanostructured lipid carrier (NLC) have higher permeability than Raloxifene in powder form and
the RNLCs are superior to Raloxifene solution.
5

Chapter 2: Materials and Method

2.1 Materials
The raloxifene hydrochloride (RLX, C28H27NO4S.HCL), lot number E8NLJ-LT and
molecular weight 510.05 g/mol was ordered from TCI chemicals, USA. The glyceryl
monostearate (lot number A63867 and molecular weight 231.3 g/mol was purchased from AA
Blocks (San Diego, CA, USA). The surfactant, poloxamer 407 (Polyethylene-Polypropylene
Glycol, P407) was procured form Spectrum chemicals. The oleic acid was procured from Sigma
Aldrich. Dialysis membrane (MWCO: 10,000 Da) were purchased from Sigma Aldrich (St.
Louis, MO). Fetal Bovine Serum (FBS) and Penicillin-streptomycin (10,000 U/ml) were
purchased from Gibco Thermo Fisher Scientific, USA. 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide salt (MTT reagent), and nucleus stain DAPI (4′,6-diamidino-2phenylindole) were purchased from Tocris Bioscience (MN, USA). MCF-7, a human epithelial
breast cancer cell line and Eagle’s minimum essential medium (EMEM) were purchased from
American Type Culture Collection (ATCC). All the other chemicals used were of analytical
grade.

2.2 Cell Culture
MCF-7, a human epithelial breast cancer cell was grown and maintained in complete medium
which consisted of EMEM, 10% v/v FBS and 1% 10,000 U/ml penicillin-streptomycin
antibiotics. The cell cultures were placed in an incubator (5% CO2 at 37 °C).

6

2.3 Preparation of Raloxifene Nanostructured Lipid Carriers (RNLCs)
RNLCs were formulated using the melt dispersion ultrasonication method. First both the
solid and liquid lipids were blended and melted at 75℃. After the lipids were melted completely,
the drug was added to the blend. Aqueous phase was prepared by dissolving poloxamer 407 in 20
ml distilled water under mild stirring and was maintained at same temperature as that of oil phase.
It was then added drop wise to the oil phase and both phases were mixed by the aid of agitation
at 1000 rpm for 10 minutes. The microemulsion was diluted by adding 25 ml of cold water (2-3
℃) under mechanical stirring. The resulting microemulsion was then ultrasonicated for 10
minutes to form NLCs.

Figure 2.1: Melt dispersion ultrasonication preparation method of RNLCs.

7

2.4 Analytical Method
UV-Spectroscopy was used to develop the analytical method. First, 2mg of raloxifene drug
was weighed and dissolved in 2 mL of methanol. The drug was dissolved completely by
sonicating. 9 mL of methanol was taken in separate tube and to this 1 mL of drug solution was
added. This acts as our stock solution. From the stock solution, different concentrations (1 ppm25 ppm) were prepared. Now, 200 µL of different concentration was transferred to 96-well
plate and analyzed using UV-spectrophotometer at 287 nm. From this analysis, calibration
curve was obtained with r2 value which will later be used in calculating entrapment efficiency,
loading efficiency and drug release.

2.5 Particle size and Zeta potential
Particle size and Zeta potential of RNLCs was determined using principle of dynamic light
scattering and principle of electrophoretic light scattering, respectively. The instrument used was
Malvern ZetaSizer Nano ZS90 (Malvern Instruments Ltd., UK, ZetaSizer Software Ver. 7.10).
Light source was 633 nm He-Ne laser and scattering angle was 90°. Glass cuvette and folded
capillary zeta cell were used for measuring particle size and zeta potential, respectively. For both
particle size and zeta potential, analysis was carried out after the sample was diluted with distilled
water and in triplicate at 25 °C temperature after equilibration time of 2 minutes. For particle size,
Z-average was measured along with polydispersity index (PDI).

2.6 Transmission Electron Microscope
Transmission electron microscope (TEM) was used to determine the morphology, size,
and shape of the RNLCs. For this, enough RNLCs sample was placed on EMS formvar support
film square grid, 200 Cu and allowed to air dry for 10 min. The samples were examined at
accelerating voltage of about 120 kV with 40,000 magnification.
8

2.7 Differential Scanning Calorimetry
This was carried out for the raloxifene, glyceryl monostearate, P407 and the melt
dispersion of glyceryl monostearate with drug and oleic acid. DSC 60 was used to perform the
thermal analysis. After equilibrating the heating chamber at 35℃ first, 3 mg samples were
accurately weighted and sealed in an aluminum pan. The pan loaded with sample was placed on
sample plate and an empty sealed aluminum pan on the other plate as a reference. The heating
rate was 5℃/min and the nitrogen gas flow of 50ml/min for the heating temperature range 35300℃.

2.8 Entrapment efficiency
RNLCs were first centrifuged at 5000 rpm for 15 mins to remove the unentrapped drug
from the emulsion. Then the collected supernatant was analyzed using UV spectrophotometer at
a wavelength of 287 nm (λmax). The contents of the Raloxifene drug were then determined from
the UV curve produced previously. Hence the drug entrapment efficiency and loading efficiency
was calculated using equations below.
% Entrapment efficiency =

Actual amount of drug loaded in RNLCs
Actual amount of drug used for RNLCs preparation

% Loading efficiency =

Amount of Raloxifene in NLCs
Total amount of NLCs

* 100

* 100

2.9 In Vitro Drug Release
The study was carried out for both the free raloxifene hydrochloride solution as well as
RNLCs using dialysis bag method in 5 ml of release medium with continuous stirring at 150 rpm
and 37℃. The release medium contained PBS (pH 7.4) containing 0.1% (v/v) Tween. Raloxifene
was dissolved in methanol to prepare free raloxifene hydrochloride solution (1 mg/mL). At
different time points (0.25, 0.5, 1, 2, 4, 6, 12, 24, 48, 72, 96, 120, 144 and 168, 182, 216, 264 and
9

340 h), 200 µl of samples were taken, and equal volume of media was replaced. The samples
were then analyzed using UV spectrophotometer to determine cumulative percent release of drug
at each time point.

2.10 Cytotoxicity study
To determine the cytotoxicity of the RNLCs in comparison to free raloxifene drug solution
in human epithelial breast cancer (MCF-7) cells, the MTT assay was utilized. Cells were seeded
at a cell count of 5000 cells/well on a 96 well plate in 200 μl of 1X complete medium that
constitutes of Eagle’s minimum essential medium (EMEM) long with 10% FBS and were
incubated (37°C, 5% carbon dioxide) for 24 hours. To prepare various concentrations of
raloxifene, formulations and raloxifene drug solution were diluted with FBS free EMEM medium.
After 24 h of growth, the cells were treated with both raloxifene drug solution and RNLCs and
left to incubate for 4 h. Fresh complete medium was replaced with the treatment after washing
the cells with sterile 1X PBS. 100 μl of MTT reagent (1 mg/mL) solution was added to each well
after 24 h and 48h after the cells were washed. It was then kept at incubator for 4 hours and 100
μl of dimethyl-sulfoxide was added. Microtiter plate reader was used to measure the intensity of
color of the dissolved formazan crystals. The negative and positive control were cells treated with
EMEM and 0.1% Triton X, respectively. Negative control was used to decide the cell viability.
Raloxifene were calculated graphically from concentration vs viability curves and the optical
density of control well was considered as 100% viable.

2.11 Cellular uptake
To detect the uptake of the RNLCs by MCF-7 cells, confocal microscopy was carried out.
For this first dye loaded nanoparticles and blank were prepared following the same preparation
method as RNLCs. The Cells were then seeded at a density of 2X105 cells per ml in each well of
10

the Lab-Tek II 4- chamber cover glass system. In order to achieve 80% confluency, they were
incubated for 24 hr. The medium was removed and well was washed thrice with PBS. For nuclear
staining, DAPI was added to the cells and for membrane staining Cell-mask deep red plasma stain
was added and incubated for 5-7 minutes. Before treating with dye loaded nanoparticles and blank
NLCs, cells were washed with PBS three times. The treatment was allowed to sit for 20 minutes
before microscopy. FV1200 Confocal Microscope (60x magnification) was used for fluorescence
microscopy images.

2.12 Parallel Artificial Membrane Permeability Assay (PAMPA)
The PAMPA assay was carried out to determine the membrane permeability of Raloxifene as
well as prepared RNLCs. For this, PAMPA kit from bioassay was used which provides all the
necessary components to run a parallel artificial permeability assay. For the assay, first 4%
lecithin solution was prepared by resuspending the dried lecithin with 750 µL of dodecane. The
10mM stock solutions in DMSO for test compounds was prepared. The permeability controls are
already provided as 10mM. Now from the stock solution, 500µM of test compound as well as
permeability controls were prepared in PBS which are used for the study. We also need to prepare
200µM of test compounds and permeability controls from 500µM solution. The blank was also
prepared by adding 5µL of DMSO and 245µL of PBS. The equilibrium standards and blank were
kept aside for analysis the next day. Now, 300µL of PBS was added to wells in the acceptor plate
and 5µl of lecithin solution to well membranes of the donor plate. Further, 200µL of each 500µM
test compound and permeability controls were added to the wells of donor plate in which we
previously added the lecithin. All experiments were done in triplicates. The donor plate was now
carefully place on top of the acceptor plate and incubated at room temperature for 18 hours. Next
day the liquid in acceptor plate was collected for analysis. 100µL of acceptor solution, equilibrium
standards and blank were added to the wells of UV plate and absorbance was read at 287 nm for
11

raloxifene, 280 nm for high permeability control and 270 nm for medium and low permeability
control.

2.13 Statistical Analysis
The data are represented as mean ± standard deviation and all the studies were performed
in triplicate. ANOVA, Student’s t-test and GraphPad Prism (Version 9, USA) were used for
statistical data analysis. P value <0.01 was considered significant.
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Chapter 3: Results

3.1 Particle size and Zeta potential
The size of RNLCs play a vital role in determining the stability, lymphatic uptake,
permeability and bioavailability of Raloxifene. The most stable particle size to be reported is 100
nm. Given that all NLCs sizes (100, 200 and 300 nm) can penetrate the intestine rapidly, smaller
NLCs (100 nm) was reported to show the highest pharmacokinetic parameters (maximum
concentration and area under the curve). The particle size for the formulated RNLCs was found
to be 114.8±0.98 nm with poly dispersibility index of 0.33±0.62 (Figure 3.1). The PDI less than
1 indicates a homogeneous distribution. The particle size is measured as Z- average which
indicates the mean hydrodynamic diameter of the RNLCs.

Figure 3.1: Z- average of the RNLCs
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When different formulations were made and analyzed, it was revealed that the size of
RNLCs was affected by concentration of surfactant, amount of oleic acid and ultrasonication time.
The size decreased as the amount of oleic acid increased and surfactant concentration was
decreased. The optimum ultrasonication time was 10 minutes.
The mean zeta potential of RNLCs was found to be +9.2 ±0.58 mV (Figure 3.2). The
positive zeta potential is because of the drug enriched shell of RNLCs. When cold water is added,
the temperature of the microemulsion reduces to the recrystallization temperature of the lipids
and core of the RNLCs is formed. This causes the drug to concentrate in the outer shell of the
RNLCs. Therefore, the drug-enriched outer shell and zwitterion nature of RLX support the
positive charge of the particles (Murthy et. al., 2020). Longer circulation half-life is attained for
lipid nanoparticles having positive zeta potential. Moreover, the cell surfaces are negatively charged
and the nanoparticle having positive zeta potential are more likely to be up taken by the cells.

Figure 3.2: Zeta potential of the RNLCs
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3.2 Transmission Electron Microscope
TEM images of RNLCs showed particle size ranging from 65nm to 120nm (Figure 3.3
and Figure 3.4). DLS records the hydrodynamic diameter of the particles while TEM records the
size of the particle that is fixed within a copper grid. Hence there was this difference between the
particle size obtained via DLS and TEM. This also explains the PDI of 0.339.

(a) 80,000X magnification

(b) 40,000X magnification

Figure 3.3: TEM images of RNLCs at voltage of 120 kV

3.3 Entrapment Efficiency
Entrapment efficiency (EE) was determined from standard curve developed with varying
raloxifene concentrations in methanol. Using the equation y= 0.0397x-0.0127 and the r2 value of
0.0998 obtained from the calibration curve of raloxifene in methanol (Figure 3.4), EE was found
to be 75.04%±2.75%. This shows that enough drug was loaded into the NLCs and proves the
efficient drug entrapment with right amount of lipids and surfactant. Similarly, the loading
efficiency was found to be 3.57%±1.25%
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Figure 3.4: Calibration Curve of Raloxifene HCL in Methanol

3.4 Differential Scanning Calorimetry
The DSC analysis was carried out to determine the physicochemical properties of the pure
RLX drug, the solid lipid glyceryl monostearate, the liquid lipid oleic acid, the surfactant P407
and the RNLCs formulation as the nature and physical state of the drug can affect its release from
the formulation. Figure 3.5 displays the thermal analysis of each. RLX showed a sharp peak at
286℃ which is the melting point of the RLX crystals. That peak was not seen in the RNLCs
formulation which shows the change in the degree of crystallinity. Thus, it can be confirmed that
RLX is dispersed in the lipid-oil matrix. Similarly, the peak was seen for solid lipid (glyceryl
monostearate) and the surfactant (p407) at 74℃ and 55℃ respectively and did not show vast shift
in the formulation. Hence, it can be concluded that presence of oleic acid in the formulation will
prevent the recrystallization of the drug in the formulation.
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Figure 3.5: The differential scanning calorimetry (DSC) spectra of the formulation (RNLCs),
the RLX drug (raloxifene hydrochloride pure drug), the solid lipid (Glyceryl monostearate
alone), the liquid lipid (oleic acid alone), and the surfactant (P407 alone).

3.5. In vitro drug release study
The in-vitro release study of free raloxifene and RNLCs was evaluated via dialysis method
using PBS (pH 7.4) with 0.1 % tween 80 as release media for 15 days at 37 °C. Free raloxifene
was rapidly released and reached a cumulative release of nearly 100 % within 24 hours. RNLCs
formulation on the other hand showed the complete release over longer time (168 hr or seven
days) compared with free drug (Fig. 3.6) which showed that the encapsulated drug achieved a
sustained release. Within one hour of starting the release study, the RNLCs showed a burst release
of 20.43 %. At 24 hr, the release was 55.65% and the formulation showed almost complete release
of 100.90% after the period of seven days. This shows the sustained release action of the
17

formulation, but further optimization of the formulation is required in order to extend the release
of drug for more than seven days.

Figure 3.6: Drug release profile of raloxifene from the raloxifene solution and the RNLCs
formulation up to seven days at 37℃ in a phosphate buffer at pH 7.4.

3.6. Cytotoxicity Study
MTT assay was performed on human epithelial breast cancer (MCF-7) cell line in order
to evaluate the cytotoxicity of RNLCs in comparison to raloxifene drug solution. Different
concentration ranging from 1 µM to 50 µM of treatment was used. Apart from RNLCs and drug,
the treatment group were blank formulation, media (negative control) and triton (positive control).
As shown in Figure 3.7 and Figure 3.8, at 24 hr and 48 hr of study, all the concentration of blank
formulation showed the cell viability above 85% suggesting the formulation to be biocompatible.
At 24 hr of study, lowest concentration (1 µM) ang highest concentration (50 µM) of raloxifene
drug solution showed cell viability of 48±3% and 41±2% respectively. At same timeline, lowest
concentration (1 µM) ang highest concentration (50 µM) of RNLCs formulation showed cell
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viability of 44±3% and 24±2% respectively. Whereas at 48 hr of study, lowest concentration (1
µM) ang highest concentration (50 µM) of raloxifene drug solution showed cell viability of
39±3% and 30±3% respectively. At same timeline, lowest concentration (1 µM) ang highest
concentration (50 µM) of RNLCs formulation showed cell viability of 33±2% and 16±2%
respectively. This suggest that the formulation is toxic to cells as concentration increases which
supports the use of Raloxifene as anti-cancer drug in breast cancer.

Figure 3.7: Percentage Cell viability of MCF-7 cells when treated with different concentrations
of Raloxifene drug solution, RNLCs formulation and blank formulation at 24 hr (* P<0.01)
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Figure 3.8: Percentage Cell viability of MCF-7 cells when treated with different concentrations
of Raloxifene drug solution, RNLCs formulation and blank formulation at 48 hr (* P<0.01)

3.7. Cellular Uptake Study
The cellular uptake study was carried out to understand how the NLCs interacted with the
cells. The size of nanoparticles plays an important role in cellular uptake (Zhu et.al., 2013). Other
than size, shape of the nanoparticles, their charge and surface chemistry determine the mechanism
of cellular uptake. For this study, fluorescent emitting formulation was prepared using same
preparation method as RNLCs. Instead of the drug, coumarin-6 dye was loaded into the
formulation. The MCF-7 cells were treated with dye loaded formulation for 20 minutes. The
cellular uptake increased with time for the treated cells in which nucleus was stained blue because
of Dapi, Cell Mask Red stained the cell membrane red, and the green fluorescence was observed
for stained cytoplasm of the cells. However, the green fluorescence was not observed in the
untreated cells.
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Figure 3.9: Cellular uptake study of dye loaded NLCs in MCF-7 cells at 30min, 1 hour and 2
hours using confocal microscopy.

3.8 Parallel Artificial Membrane Permeability Assay (PAMPA)
The PAMPA assay was carried out to determine the membrane permeability of Raloxifene
as well as prepared RNLCs. Following formula was used to calculate the permeability rate (Pe)
Pe = CX −ln (1 −

ODA
) cm/s
ODE

(3.1)
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Where ODA is the absorbance of Acceptor solution, ODE is the absorbance of the equilibrium
standard and using 18-hour incubation, C= 7.72*10-6. The C value is calculated as
C=

VD X VA
X Area X time cm/s
VD + VA

(3.2)

Here, VD is 0.2 cm3, VA is 0.3 cm3, membrane area is 0.24 cm2 and time is 72000 s. Using the
formula above, the permeability rate for raloxifene solution was calculated to be 8*10-6 cm/s and
for the RNLCs it was calculated to be 17.8*10-6 cm/s. The Pe value greater than 10*10-6 is
considered to be high permeability, Pe less than 1*10-6 to be low permeability and value that falls
between 1*10-6 and 10*10-6 to be medium permeability values. Hence, from the Pe calculated for
raloxifene solution and RNLCs we can conclude that raloxifene when formulated as NLCs have
increased permeability.

Figure 3.10: Permeability rate of test compounds after 20 hr incubation.
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Chapter 4: Discussion

The particle size for the formulated RNLCs was found to be 114.8±0.98 nm. TEM images
showed the particle size ranging from 65nm to 120nm. The size of RNLCs play a vital role in
determining the stability, lymphatic uptake, permeability and bioavailability of Raloxifene. The
most stable particle size to be reported is 100 nm. Given that all NLCs sizes (100, 200 and 300
nm) can penetrate the intestine rapidly, smaller NLCs (100 nm) was reported to show the highest
pharmacokinetic parameters (maximum concentration and area under the curve). When different
formulations were made and analyzed, it was revealed that the size of RNLCs was affected by
concentration of surfactant, amount of oleic acid and ultrasonication time. The size decreased as
the amount of oleic acid increased and surfactant concentration was decreased. The optimum
ultrasonication time was 10 minutes. The mean zeta potential of RNLCs was found to be
+9.21±0.58 mV. The positive zeta potential is because of the drug enriched shell of RNLCs. When
cold water is added, the temperature of the microemulsion reduces to the recrystallization
temperature of the lipids and core of the RNLCs is formed. This causes the drug to concentrate
in the outer shell of the RNLCs. Therefore, the drug-enriched outer shell and zwitterion nature of
RLX support the positive charge of the particles (Murthy et. al., 2020). Similarly, entrapment
efficiency was found to be 75.04%±2.75%. This shows that enough drug was loaded into the
NLCs and proves the efficient drug entrapment with right amount of lipids and surfactant.
As the nature and physical state of the drug can affect its release from the formulation, the
DSC analysis was carried out to determine the physicochemical properties of the pure RLX drug,
the solid lipid glyceryl monostearate, the liquid lipid oleic acid, the surfactant P407 and the
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RNLCs formulation. If we see the peaks of drug in the formulation, it means that the drug is not
encapsulated into the formulation. Figure 3.5 displays the thermal analysis of each component
used in the formulation. RLX showed a sharp peak at 286 ℃ which is the melting point of the
RLX crystals. That peak was not seen in the RNLCs formulation which shows the change in the
degree of crystallinity. Thus, it can be confirmed that RLX is dispersed in the lipid-oil matrix and
that the presence of oleic acid in the formulation will prevent the recrystallization of the drug in
the formulation. The in-vitro release study of free raloxifene and RNLCs was evaluated via
dialysis method using PBS (pH 7.4) with 0.1 % tween 80 as release media for 15 days at 37 °C.
This was done in order to correlate the in vivo drug release pattern. Free raloxifene was rapidly
released and reached a cumulative release of nearly 100 % within 24 hr. RNLCs formulation on
the other hand showed the complete release over longer time (168 hr or seven days) compared
with free drug (Fig. 6) which showed that the encapsulated drug achieved a sustained release, but
further optimization of the formulation is required in order to extend the release of drug for more
than seven days.
Cell viability is an important parameter to study toxic effects of the drug. MTT assay was
performed on human epithelial breast cancer (MCF-7) cell line in order to evaluate the
cytotoxicity of RNLCs in comparison to raloxifene drug solution. As shown in figure 3.7 and
Figure 3.8, at 24 hr and 48 hr of study, all the concentration of blank formulation showed the cell
viability above 85% suggesting the formulation to be biocompatible. At both 24 hr and 48 hr of
study, the cell viability for RNLCs formulation was less than the drug solution. This suggest that
the formulation is more toxic to cells as concentration increases which supports the use of
Raloxifene as anti-cancer drug in breast cancer. Many other researchers have also established the
decreased cell viability of MCF-7 cell line when treated with raloxifene. Raloxifene efficiently
attenuated cell growth and induced cell death in a concentration-dependent manner where 10 µM
raloxifene, killed about 50% of cell within 48 hr (Dong Eun Kim et al.). Further improved cell
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cytotoxicity was established in another research (Aldawsari & Negm, 2020). In this research, the
self-nano-emulsion drug delivery system (SNEDDS) of raloxifene was more potent than the
raloxifene solution.
The cellular uptake study was carried out to understand how the NLCs interacted with the
cells. The MCF-7 cells were treated with dye loaded formulation for 20 minutes. The cellular
uptake increased with time for the treated cells. This further provides explanation for the sustained
release pattern of the formulation. Membrane permeability is an important characteristic that
should be determined as drugs often need to cross cell membrane in order to reach their target of
action. Permeability can be evaluated by cell-based methods which are generally time consuming
and expensive. For quick and easy analysis of permeability, PAMPA method is utilized. Using
the PAMPA, the permeability rate for raloxifene solution was calculated to be 8*10-6 cm/s and
for the RNLCs it was calculated to be 17.8*10-6 cm/s. The Pe value greater than 10*10-6 is
considered to be high permeability, Pe less than 1*10-6 to be low permeability and value that falls
between 1*10-6 and 10*10-6 to be medium permeability values. Hence, from the Pe calculated for
raloxifene solution and RNLCs we can conclude that raloxifene when formulated as NLCs have
increased permeability.
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Chapter 5: Conclusion

Raloxifene nanostructured lipid carriers (RNLCs) were successfully prepared using
melt dispersion ultrasonication method. The prepared RNLCs were characterized, and the in-vitro
studies were carried out in the human epithelial breast cancer cell line (MCF-7 cell line). The
RNLCs have a size of 114.8±0.98 nm and zeta potential of +9.21±0.58 mV. With an entrapment
efficiency of 75.04%±2.75%, the RNLCs showed sustained release over seven days’ time
compared to 24 hours for raloxifene drug solution. The prepared RNLCs were successfully take
up by the MCF-7 cells in time dependent manner and the RNLCs showed decreased cell viability
compared to raloxifene drug. This suggests the RNLCs were more potent than the raloxifene
drug. From the permeability rate calculated for raloxifene solution and RNLCs, we can conclude
that raloxifene when formulated as NLCs have increased permeability. Overall, the prepared
RNLCs were found to be superior than the raloxifene drug as such.
Many researchers have been able to increase the bioavailability of raloxifene through
different formulations. The aim of this research was to increase the permeability of raloxifene
through lipid-based formulation. Because of poor aqueous solubility, the high permeability
characteristic of raloxifene becomes negligible leading to poor bioavailability. Lipid based
formulations are believed to by-pass first pass metabolism that will lead to increased
bioavailability. But we cannot say if or not the bioavailability is increased based only on
increased permeability. Further analysis is required for that. One can carry out UGT-inhibition
assay to see if the nanoparticles are metabolically stable. Also, in vivo analysis can be carried
out to calculate the bioavailability of raloxifene. Further, the cytotoxicity study can be extended
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to 72 hr and also to normal cell line to see the effect of formulation in normal cells. Moreover,
stability studies can be carried out for the formulation. This can be accomplished by storing the
formulation for longer time period and examining the change in particle size, zeta potential,
entrapment efficiency and in-vitro drug release at regular time intervals. The effect of sonication
time and different concentrations of oleic acid and surfactant on particle size was observed in this
research. There is one more parameter that could lead to change in particle size and that is drop
wise addition of aqueous phase to oil phase. How fast or how slowly we add the aqueous phase
can also change the particle size. This can be further analyzed.
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